Immune Polarization in Coexisting Rheumatoid Arthritis and Asthma: Insights into Th2 Dominance and Unresolved Confounding Authors: Nedim Kaban Published: 2026 Dear Editor, We read with great interest the article by Almutairi et al. [1] which investigated T helper (Th) cytokine profiles in patients with rheumatoid arthritis (RA), bronchial asthma (BA), and coexisting RA and BA (BARA). The authors reported that BARA patients exhibited a predominantly Th2-skewed cytokine profile resembling BA, in contrast to the relatively Th1/Th17-oriented pattern observed in RA alone. These findings provide valuable primary data on systemic immune polarization in overlapping inflammatory diseases. In this cross-sectional study of 25 patients per group, asthma-related cohorts demonstrated a relative Th2 bias, whereas RA patients showed higher Th1/Th17 cytokines such as interferon-γ and IL-17 family members [1]. Notably, specific Th2 cytokines differed by comparison: IL-5 was higher in BA than RA, IL-4 was higher in BARA than RA, and IL-10 was elevated in both asthma groups. Despite these nuanced differences, the overall similarity between BA and BARA profiles suggested that asthma-associated type 2 immune pathways may predominate systemic immune signatures in patients with both conditions. This aligns with established asthma immunobiology, in which type 2 cytokines such as IL-4, IL-5, and IL-13 drive allergic airway inflammation [2]. Despite its strengths, several methodological considerations merit attention. First, the potential confounding effect of background pharmacotherapy remains unaddressed; specifically, differential exposure to corticosteroids or conventional disease-modifying anti-rheumatic drugs such as methotrexate between groups could independently influence Th1/Th2 polarization and cytokine production. Without detailed treatment stratification, it is difficult to disentangle disease-related immune signatures from medication effects. Second, standardized measures of disease activity and duration were not reported for either RA or asthma. Given that cytokine expression can vary with disease activity, inclusion of such indices would strengthen clinical interpretation. Moreover, asthma sub-phenotypes, including atopic versus non-atopic and obesity-related forms, were not specified. Considering the marked heterogeneity of asthma, detailed endotyping could help clarify whether the observed Th2 dominance in BARA reflects specific asthma subtypes rather than a uniform disease entity. This is particularly relevant given emerging data that certain asthma phenotypes may deviate from classic type 2 inflammation. In summary, Almutairi et al. [1] provide important insights into immune polarization in RA, BA, and BARA. Future studies incorporating detailed treatment data, standardized activity measures, and refined asthma endotyping, ideally in a longitudinal design, will be essential to translate these immunological observations into personalized clinical strategies. Acknowledgments The author would like to thank the editors for considering this letter. Conflict of Interest Statement The author declared no conflicts of interest. Funding Sources This paper received no external funding. Author Contributions Nedim Kaban was responsible for the conception, analysis, drafting, and final approval of the manuscript.